Conditions: End Stage Renal Disease
Keywords: End stage Renal disease
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 72
Healthy volunteers: yes

Brief summary:
This study is being conducted to assess any potential differences in the absorption and excretion between two lanthanum carbonate formulations. This study is also being done to assess the safety and tolerability of the two lanthanum carbonate formulations.

Detailed description:

Arms:
arm 1: Lanthanum carbonate granulated formulation crossover to chewable tablet formulation arm 2: Lanthanum carbonate chewable table formulation crossover to granulated formulation

Interventions: intervention 1: Lanthanum carbonate Granule Formulation intervention 2: Lanthanum carbonate Chewable Tablets (Fosrenol)
Intervention descriptions: intervention 1: 3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.) intervention 2: 3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)

Protocol document: